Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.
Kantarjian
Hagop M
HM
Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Cortes
Jorge E
JE
Rowe
Jacob M
JM
Kurzrock
Razelle
R
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D051231:Farnesyltranstransferase; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase